Edwards Lifesciences (EW) Stock Forecast & Price Target

Compare

1,919 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EW Analyst Ratings

Moderate Buy

15 Buy

9 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Edwards

Lifesciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EW Stock 12 Month Forecast

Average Price Target

$95.86

▲(12.99% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $95.86 with a high forecast of $104.00 and a low forecast of $84.00. The average price target represents a 12.99% change from the last price of $84.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"69":"$69","78":"$78","87":"$87","96":"$96","105":"$105"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$104.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$95.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$84.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[69,78,87,96,105],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.27,86.71076923076923,88.15153846153846,89.59230769230768,91.03307692307692,92.47384615384615,93.91461538461539,95.35538461538461,96.79615384615384,98.23692307692308,99.67769230769231,101.11846153846153,102.55923076923077,{"y":104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.27,86.08461538461538,86.89923076923077,87.71384615384615,88.52846153846154,89.34307692307692,90.1576923076923,90.9723076923077,91.78692307692307,92.60153846153845,93.41615384615385,94.23076923076923,95.04538461538462,{"y":95.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.27,85.17230769230768,85.07461538461538,84.97692307692307,84.87923076923077,84.78153846153846,84.68384615384615,84.58615384615385,84.48846153846154,84.39076923076922,84.29307692307692,84.19538461538461,84.09769230769231,{"y":84,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":70.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$104.00

Average Price Target$95.86

Lowest Price Target$84.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robbie Marcus

J.P. Morgan

$90→$100

Buy

17.87%

Upside

Upgraded

12/18/25

Edwards Lifesciences: Buy Rating on Structural Heart Leadership, Accelerating TAVR/TMTT Growth, and Durable Double‑Digit Upside

William Plovanic

Canaccord Genuity

$89→$87

Hold

2.55%

Upside

Reiterated

12/17/25

Edwards Lifesciences price target lowered to $87 from $89 at CanaccordEdwards Lifesciences price target lowered to $87 from $89 at Canaccord

Adam Maeder

Piper Sandler

$95

Buy

11.98%

Upside

Reiterated

12/16/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Travis Steed

Bank of America Securities

$103

Buy

21.40%

Upside

Reiterated

12/16/25

Edwards Lifesciences: Buy Rating Backed by Strategic Initiatives and Expanding Market Potential

David Rescott

Robert W. Baird

$88→$87

Hold

2.55%

Upside

Reiterated

12/16/25

Edwards Lifesciences (EW) Gets a Hold from Robert W. Baird

Shagun Singh Chadha

RBC Capital

$100

Buy

17.87%

Upside

Reiterated

12/16/25

RBC Capital Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Brandon Vazquez

William Blair

Buy

―

Reiterated

12/16/25

Positive Outlook for Edwards Lifesciences Amid CMS Coverage Expansion for TAVR Procedures

Marie Thibault

BTIG

$103

Buy

21.40%

Upside

Reiterated

12/15/25

Buy Rating for Edwards Lifesciences Amid Potential TAVR Coverage Expansion and Strategic Alignment

Joanne Wuensch

Citi

$96→$101

Buy

19.05%

Upside

Reiterated

12/12/25

Edwards Lifesciences price target raised to $101 from $96 at CitiEdwards Lifesciences price target raised to $101 from $96 at Citi

Matt Miksic

Barclays

$99→$103

Buy

21.40%

Upside

Reiterated

12/08/25

Edwards Lifesciences (EW) Gets a Buy from Barclays

Richard Newitter

Truist Financial

$90→$92

Hold

8.44%

Upside

Reiterated

12/05/25

Truist Financial Remains a Hold on Edwards Lifesciences (EW)

Matthew Taylor

Jefferies

$102

Buy

20.23%

Upside

Reiterated

12/05/25

Jefferies Keeps Their Buy Rating on Edwards Lifesciences (EW)

Larry Biegelsen

Wells Fargo

$95→$96

Buy

13.15%

Upside

Reiterated

12/05/25

Edwards Lifesciences price target raised to $96 from $95 at Wells FargoEdwards Lifesciences price target raised to $96 from $95 at Wells Fargo

Danielle Antalffy

UBS

$90→$92

Hold

8.44%

Upside

Reiterated

12/05/25

Edwards Lifesciences (EW) Gets a Hold from UBS

Rick Wise

Stifel Nicolaus

$95→$100

Buy

17.87%

Upside

Reiterated

12/05/25

Stifel Nicolaus Keeps Their Buy Rating on Edwards Lifesciences (EW)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robbie Marcus

J.P. Morgan

$90→$100

Buy

17.87%

Upside

Upgraded

12/18/25

Edwards Lifesciences: Buy Rating on Structural Heart Leadership, Accelerating TAVR/TMTT Growth, and Durable Double‑Digit Upside

William Plovanic

Canaccord Genuity

$89→$87

Hold

2.55%

Upside

Reiterated

12/17/25

Edwards Lifesciences price target lowered to $87 from $89 at CanaccordEdwards Lifesciences price target lowered to $87 from $89 at Canaccord

Adam Maeder

Piper Sandler

$95

Buy

11.98%

Upside

Reiterated

12/16/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Travis Steed

Bank of America Securities

$103

Buy

21.40%

Upside

Reiterated

12/16/25

Edwards Lifesciences: Buy Rating Backed by Strategic Initiatives and Expanding Market Potential

David Rescott

Robert W. Baird

$88→$87

Hold

2.55%

Upside

Reiterated

12/16/25

Edwards Lifesciences (EW) Gets a Hold from Robert W. Baird

Shagun Singh Chadha

RBC Capital

$100

Buy

17.87%

Upside

Reiterated

12/16/25

RBC Capital Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Brandon Vazquez

William Blair

Buy

―

Reiterated

12/16/25

Positive Outlook for Edwards Lifesciences Amid CMS Coverage Expansion for TAVR Procedures

Marie Thibault

BTIG

$103

Buy

21.40%

Upside

Reiterated

12/15/25

Buy Rating for Edwards Lifesciences Amid Potential TAVR Coverage Expansion and Strategic Alignment

Joanne Wuensch

Citi

$96→$101

Buy

19.05%

Upside

Reiterated

12/12/25

Edwards Lifesciences price target raised to $101 from $96 at CitiEdwards Lifesciences price target raised to $101 from $96 at Citi

Matt Miksic

Barclays

$99→$103

Buy

21.40%

Upside

Reiterated

12/08/25

Edwards Lifesciences (EW) Gets a Buy from Barclays

Richard Newitter

Truist Financial

$90→$92

Hold

8.44%

Upside

Reiterated

12/05/25

Truist Financial Remains a Hold on Edwards Lifesciences (EW)

Matthew Taylor

Jefferies

$102

Buy

20.23%

Upside

Reiterated

12/05/25

Jefferies Keeps Their Buy Rating on Edwards Lifesciences (EW)

Larry Biegelsen

Wells Fargo

$95→$96

Buy

13.15%

Upside

Reiterated

12/05/25

Edwards Lifesciences price target raised to $96 from $95 at Wells FargoEdwards Lifesciences price target raised to $96 from $95 at Wells Fargo

Danielle Antalffy

UBS

$90→$92

Hold

8.44%

Upside

Reiterated

12/05/25

Edwards Lifesciences (EW) Gets a Hold from UBS

Rick Wise

Stifel Nicolaus

$95→$100

Buy

17.87%

Upside

Reiterated

12/05/25

Stifel Nicolaus Keeps Their Buy Rating on Edwards Lifesciences (EW)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

1 Month

xxx

Success Rate

28/41 ratings generated profit

Average Return

+2.10%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 68.29% of your transactions generating a profit, with an average return of +2.10% per trade.

3 Months

xxx

Success Rate

16/23 ratings generated profit

Average Return

+3.18%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +3.18% per trade.

1 Year

Adam MaederPiper Sandler

Success Rate

17/23 ratings generated profit

Average Return

+8.05%

reiterated a buy rating 3 days ago

Copying Adam Maeder's trades and holding each position for 1 Year would result in 73.91% of your transactions generating a profit, with an average return of +8.05% per trade.

2 Years

xxx

Success Rate

27/41 ratings generated profit

Average Return

+19.45%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 65.85% of your transactions generating a profit, with an average return of +19.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EW Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EW has received 43 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. EW average Analyst price target in the past 3 months is 95.86.

Each month's total comprises the sum of three months' worth of ratings.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is $0.62 with a range of $0.60 to $0.65. The previous quarter’s EPS was $0.67. EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is $1.55B with a range of $1.50B to $1.60B. The previous quarter’s sales results were $1.55B. EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Stock Forecast FAQ

What is EW’s average 12-month price target, according to analysts?

Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 95.86.

What is EW’s upside potential, based on the analysts’ average price target?

Edwards Lifesciences has 12.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EW a Buy, Sell or Hold?

Edwards Lifesciences has a consensus rating of Moderate Buy which is based on 15 buy ratings, 9 hold ratings and 0 sell ratings.

What is Edwards Lifesciences’s price target?

The average price target for Edwards Lifesciences is 95.86. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $104.00 ,the lowest forecast is $84.00. The average price target represents 12.99% Increase from the current price of $84.84.

What do analysts say about Edwards Lifesciences?

Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of EW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Edwards Lifesciences (EW) Stock Forecast & Price Target

EW Analyst Ratings

EW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edwards Lifesciences

EW Analyst Recommendation Trends

EW Financial Forecast

EW Earnings Forecast

EW Sales Forecast

EW Stock Forecast FAQ

Detailed List of Analyst Forecasts